Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study

FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) Arch Therapeutics, Inc. (OTCQB:ARTH) ( Arch or the Company ), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin sensitization study and that applications of the Company’s AC5™ Topical Gel are underway for all subjects. The study is anticipated to conclude during the third quarter. Terrence W. Norchi, MD, President and CEO of Arch, said, This study is an important component of The post Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study appeared first on Public Wire.
http://bit.ly/2yltsuG